Borys Hrinczenko
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Borys Hrinczenko has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Andres Forero-Torres
University of Alabama at Birmingham
1 shared publication - Anja von Heydebreck
Merck KGaA, Darmstadt, Germany
1 shared publication Cleveland Ronald
1 shared publication- Erika Hamilton
Sarah Cannon Research Institute, Nashville, TN, USA
1 shared publication - Guy Jerusalem
CHU Liège and Liège University, Liège, Belgium
1 shared publication - Hans Juergen Grote
Merck KGaA, Darmstadt, Germany
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 23 October 2017
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 167 (3) , 671-686
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
Purpose Agents targeting programmed death receptor 1 (PD-1) or its ligand (PD-L1) have shown antitumor activity in the treatment of metastatic breast cancer (MBC). The aim of this study was to assess the activity of avelumab, a PD-L1 inhibitor, in patients with MBC. Methods In a phase 1 trial (JAVELIN Solid Tumor; NCT01772004), patients with MBC refractory to or progressing after standard-of-care therapy received avelumab intravenously 10 mg/kg every 2 weeks. Tumors were assessed every 6 weeks by RECIST v1.1. Adverse events (AEs) were graded by NCI-CTCAE v4.0. Membrane PD-L1 expression was assessed by immunohistochemistry (Dako PD-L1 IHC 73-10 pharmDx). Results A total of 168 patients with MBC, including 58 patients with triple-negative breast cancer (TNBC), were treated with avelumab for 2–50 weeks and followed for 6–15 months. Patients were heavily pretreated with a median of three prior therapies for metastatic or locally advanced disease. Grade ≥ 3 treatment-related AEs occurred in 13.7% of patients, including two treatment-related deaths. The confirmed objective response rate (ORR) was 3.0% overall (one complete response and four partial responses) and 5.2% in patients with TNBC. A trend toward a higher ORR was seen in patients with PD-L1+ versus PD-L1− tumor-associated immune cells in the overall population (16.7% vs. 1.6%) and in the TNBC subgroup (22.2% vs. 2.6%). Conclusion Avelumab showed an acceptable safety profile and clinical activity in a subset of patients with MBC. PD-L1 expression in tumor-associated immune cells may be associated with a higher probability of clinical response to avelumab in MBC.
- 23 October 2017
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 167 (3) , 671-686
Top Cited PapersOpen AccessAvelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
Purpose Agents targeting programmed death receptor 1 (PD-1) or its ligand (PD-L1) have shown antitumor activity in the treatment of metastatic breast cancer (MBC). The aim of this study was to assess the activity of avelumab, a PD-L1 inhibitor, in patients with MBC. Methods In a phase 1 trial (JAVELIN Solid Tumor; NCT01772004), patients with MBC refractory to or progressing after standard-of-care therapy received avelumab intravenously 10 mg/kg every 2 weeks. Tumors were assessed every 6 weeks by RECIST v1.1. Adverse events (AEs) were graded by NCI-CTCAE v4.0. Membrane PD-L1 expression was assessed by immunohistochemistry (Dako PD-L1 IHC 73-10 pharmDx). Results A total of 168 patients with MBC, including 58 patients with triple-negative breast cancer (TNBC), were treated with avelumab for 2–50 weeks and followed for 6–15 months. Patients were heavily pretreated with a median of three prior therapies for metastatic or locally advanced disease. Grade ≥ 3 treatment-related AEs occurred in 13.7% of patients, including two treatment-related deaths. The confirmed objective response rate (ORR) was 3.0% overall (one complete response and four partial responses) and 5.2% in patients with TNBC. A trend toward a higher ORR was seen in patients with PD-L1+ versus PD-L1− tumor-associated immune cells in the overall population (16.7% vs. 1.6%) and in the TNBC subgroup (22.2% vs. 2.6%). Conclusion Avelumab showed an acceptable safety profile and clinical activity in a subset of patients with MBC. PD-L1 expression in tumor-associated immune cells may be associated with a higher probability of clinical response to avelumab in MBC.
- Open Access
- 1 January 2013
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 4
Immune dysregulation in sickle cell disease
Acute painful vaso-occlusive crises and recurrent infections are frequent complications of patients with sickle cell disease (SCD). Chronic activation of monocytes producing pro-inflammatory cytokines may play a role in immune dysregulation, susceptibility to infection, activation of vascular endothelium, and vaso-occlusion in SCD. The pathophysiology of SCD may be influenced by activated and/or immature monocytes. We compared activated monocytes in SCD with normal monocytes in healthy persons, analyzing CD4, CD14, CD16, and HLA-DR antigen expression using flow cytometry and morphologic assessment of monocytes with Wright and alpha-naphthyl butyrate esterase (ANBE) stains. SCD patients showed absolute monocytosis and decreased CD4+, CD4+HLA-DR+ and CD4+CD14+ monocyte expression and increased CD14(dim)+CD16+ expression. Monocytes in SCD showed immature morphology, including a high N/C ratio, indented nuclei, decreased cytoplasmic vacuolation and ANBE activity. We also examined the function of dendritic cells in SCD. Peripheral blood dendritic cells (PBDC) were purified from patients with SCD and from healthy donors. Monocyte-derived DC (MoDC) from patients and donors were generated in vitro with granulocyte/macrophage colony stimulating factor (GMCSF) and interleukin-(IL-)-4. Compared to healthy donors, PBDC from SCD patients showed reduced expression of HLA-DR, CD80, CD86, and CD40; reduced stimulatory capacity to mixed lymphocyte reactions; and reduced production of IL-12 in response to lipopolysaccharide and to CD40 ligand. Similar reductions were observed in MoDC from SCD patients. These results indicate that alterations in dendritic cell function are present in SCD patients. Alterations in both monocytes and dendritic cells in SCD may contribute to deficiencies in immune response and susceptibility to infection.
- 1 January 2013
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 4
Open AccessImmune dysregulation in sickle cell disease
Acute painful vaso-occlusive crises and recurrent infections are frequent complications of patients with sickle cell disease (SCD). Chronic activation of monocytes producing pro-inflammatory cytokines may play a role in immune dysregulation, susceptibility to infection, activation of vascular endothelium, and vaso-occlusion in SCD. The pathophysiology of SCD may be influenced by activated and/or immature monocytes. We compared activated monocytes in SCD with normal monocytes in healthy persons, analyzing CD4, CD14, CD16, and HLA-DR antigen expression using flow cytometry and morphologic assessment of monocytes with Wright and alpha-naphthyl butyrate esterase (ANBE) stains. SCD patients showed absolute monocytosis and decreased CD4+, CD4+HLA-DR+ and CD4+CD14+ monocyte expression and increased CD14(dim)+CD16+ expression. Monocytes in SCD showed immature morphology, including a high N/C ratio, indented nuclei, decreased cytoplasmic vacuolation and ANBE activity. We also examined the function of dendritic cells in SCD. Peripheral blood dendritic cells (PBDC) were purified from patients with SCD and from healthy donors. Monocyte-derived DC (MoDC) from patients and donors were generated in vitro with granulocyte/macrophage colony stimulating factor (GMCSF) and interleukin-(IL-)-4. Compared to healthy donors, PBDC from SCD patients showed reduced expression of HLA-DR, CD80, CD86, and CD40; reduced stimulatory capacity to mixed lymphocyte reactions; and reduced production of IL-12 in response to lipopolysaccharide and to CD40 ligand. Similar reductions were observed in MoDC from SCD patients. These results indicate that alterations in dendritic cell function are present in SCD patients. Alterations in both monocytes and dendritic cells in SCD may contribute to deficiencies in immune response and susceptibility to infection.